Catherine Novack : Right. And what’s the level of interest across different areas of the U.S.?
Sabrina Martucci Johnson : Yeah. Fantastic question. So the sites are spread across the country. So, pretty, good diversity across the country in terms of where the sites are. And that also means there’s some diversity in terms of kind of what the reproductive right landscape is in a particular state, where that site is. What we’ve seen across the board and these are investigators that have all participated in lots of contraceptive studies and are very experienced in that regard, their view is that obviously, it’s a factor, right? It’s something that people are considering and certainly people that are signing up for a contraceptive study, by definition they have to be open to the fact that they may get pregnant right? It’s an investigational product.
And so they have to be aware that that is a factor. And where they reside that may be more meaningful to them than maybe in a different state in terms of what their propensity and comfort with that is. But all of the sites feel that, none of them have really projected that it would change how they anticipate enrollment progressing. Because their view is that it’s always a consideration anyhow and then, in general people who tend to participate in contraceptive studies generally have a good acceptance of the fact that they may get pregnant and are prepared for that outcome. But it’s definitely something that has been [Aidio Gap] Sort of the cost providing the Ovaprene supplies for the study. And then, the way the creative works is Daré puts funds into basically to the NIH basically into an account for use in the study.
So we have contributed our $5 million today to that account. There’s another $500,000 that we would anticipate right now providing this year to support the study, as well. And those funds should be sufficient. However, clinical trial costs can vary, right, as you’ve said as progress things happen, right? Or if we add additional sites so there are a number of factors that could change the cost of the study. And so if that happens, then we and the NIH would come together and decide what our contribution would be, what their contribution would be if that were to happen and adjust accordingly. But right now, like we’ve put our monies there and those are the funds along with support from the NIH to conduct the study.
Catherine Novack : Okay, that’s very helpful. Thanks for taking my questions. Have a great afternoon.
Sabrina Martucci Johnson : Yeah. Thank you.
Operator: [Operator Instructions] Your next question comes from the line of Michael Elsa – Michael. I’m sorry, but I think we lost Michael. Okay. So there are no further questions at this time, I would like to turn the call back over to our presenters.
Sabrina Martucci Johnson : Alright. Well, thank you for taking the time this afternoon to hear about our recent updates and ongoing commitment to drive value for Daré stakeholders, women, health care providers, and our shareholders. With our diverse portfolio, we seek to bring to market differentiated prescription therapies that prioritize women’s health and well-being expand treatment options where none exists, enhance outcomes where current standard-of-care has meaningful shortcomings and improve ease of use for women, where a more compelling form factor can drive adoption, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. We definitely look forward to keeping you updated on our progress towards the milestones we discussed today.
